The HIV Vaccine's Path Through Clinical Trials: A Biotech CEO's Perspective

Villanova Health Summit

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

7y ago

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on June 27, 2023 07:01 (10M ago). Last successful fetch was on March 16, 2021 16:49 (3y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Host: Matt Birnholz, MD
Guest: Robert McNally, MD
From the Villanova Health Summit's Speaker Event, host Dr. Matt Birnholz speaks with guest Dr. Robert McNally, President, and CEO of GeoVax, Inc. They discuss the challenges that biotech companies face when bringing vaccines through clinical trials, and the long-term project being conducted by his colleagues to deliver an HIV vaccine to market.

26 episodes

#Science #Health and Well-Being #Medicine #Ethics #ReachMD